Fate Therapeutics, Inc. is a clinical‐stage biopharmaceutical company focused on the development of first‐in‐class cellular immunotherapies for cancer and immune disorders. The company leverages its proprietary induced pluripotent stem cell (iPSC) platform to create off‐the‐shelf natural killer (NK) and T‐cell products designed to overcome limitations of donor‐derived approaches. Fate’s research aims to deliver therapies with consistent quality, increased potency and scalable manufacturing for broad patient access.
Central to Fate’s pipeline are multiple iPSC‐derived cell therapy candidates in active clinical development. Key programs include FT596, an NK cell candidate targeting CD19‐positive lymphoid malignancies; FT538, an NK cell therapy engineered for acute myeloid leukemia; and FT819, an iPSC‐derived CAR T‐cell product for multiple myeloma. The company’s platform also supports early‐stage efforts in autoimmune and inflammatory diseases, with preclinical programs exploiting novel mechanisms of immune modulation.
Founded in 2007 and headquartered in La Jolla, California, Fate Therapeutics completed its initial public offering on the Nasdaq Stock Market in December 2013. The company has established strategic collaborations with pharmaceutical partners, including Biogen and Janssen Biotech, to advance selected cell therapy candidates. Clinical trials are underway across North America and in select international sites.
Under the leadership of President and Chief Executive Officer Scott Wolchko, M.D., Fate Therapeutics continues to expand its manufacturing capabilities and clinical footprint. The company’s global efforts seek to bring standardized, off‐the‐shelf cell therapies to patients with limited treatment options, addressing unmet medical needs in oncology and immune dysregulation.
AI Generated. May Contain Errors.
Free FATE Stock Alerts